Nature Reviews Neurology - Table of Contents alert Volume 12 Issue 2

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
February 2016 Volume 12 Number 2
Impact Factor 15.358 *	In this issue Research Highlights Year in Review Reviews Perspectives Also this month  Featured article: Randomized trials of endovascular therapy for stroke — impact on stroke care Maxim Mokin, Haydy Rojas & Elad I. Levy
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
An open access journal dedicated to highlighting the most important scientific advances in Parkinson's disease research, spanning the motor and non-motor disorders of Parkinson's disease. Part of the Nature Partner Journals series, npj Parkinson's Disease is published in partnership with the Parkinson's Disease Foundation.  Open for submissions
RESEARCH HIGHLIGHTS Top Neuromuscular disease: Genome editing shows promise in an in vivo model of Duchenne muscular dystrophy Published online: 18 January 2016 p63 | doi:10.1038/nrneurol.2016.4 PDF Neurodevelopmental disorders: Fetal exposure to antiepileptic drugs could affect brain activity in newborns Published online: 18 January 2016 p64 | doi:10.1038/nrneurol.2016.3 PDF Alzheimer disease: Blocking microglial proliferation halts Alzheimer disease in mice Published online: 22 January 2016 p64 | doi:10.1038/nrneurol.2016.6 PDF Nature Reviews Neurology JOBS of the week Professor of Neurology (Ladder Rank or In Residence Faculty Series) University of California - San Francisco, School of Medicine More Science jobs from Nature Reviews Neurology EVENT WCNR 2016: 9th World Congress for NeuroRehabilitation 10.05.16 Philadelphia, USA More science events from
YEAR IN REVIEW		Top
Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD Lorraine V. Kalia & Anthony E. Lang Published online: 18 January 2016 p65 | doi:10.1038/nrneurol.2015.249 Important advances in Parkinson disease (PD) in 2015 included a revision of its clinical diagnostic criteria and a proposal for research criteria defining prodromal PD. Research published in the past year has also continued to expand our understanding of the roles of Lewy pathology and α-synuclein in the pathobiology of PD. Full Text | PDF
Stroke in 2015: Acute endovascular recanalization therapy comes of age Alejandro A. Rabinstein Published online: 08 January 2016 p67 | doi:10.1038/nrneurol.2015.241 The past year has seen practice-changing findings in stroke research. Strong evidence now supports endovascular thrombectomy as the new gold standard of care in acute ischaemic stroke, and a pragmatic trial raised concerns over early intensive mobilization after stroke. Moreover, new insights were gained into the trajectory of stroke-associated cognitive decline. Full Text | PDF
Neuro-oncology in 2015: Progress in glioma diagnosis, classification and treatment Patrick Y. Wen & David A. Reardon Published online: 18 January 2016 p69 | doi:10.1038/nrneurol.2015.242 Gliomas are the most common form of malignant primary brain tumour. In the past year, substantial progress has been made in the classification and treatment of lower-grade gliomas (WHO grades II and III), and the FDA has approved a new therapy for newly diagnosed glioblastomas. Full Text | PDF
Multiple sclerosis in 2015: Managing the complexity of multiple sclerosis Olga Ciccarelli & Alan Thompson Published online: 29 January 2016 p70 | doi:10.1038/nrneurol.2016.2 The application of imaging biomarkers has provided new insights into the mechanisms of damage in multiple sclerosis (MS) and the risk of MS development and progression. The goal of eliminating all disease activity requires a timely escalation of treatment. This increasing complexity is compounded by the need to treat comorbidities. Full Text | PDF
Epilepsy in 2015: Classic antiepileptic drugs under fire, and new options emerge Christian E. Elger Published online: 22 January 2016 p72 | doi:10.1038/nrneurol.2016.1 Diagnosis and management of epilepsy remain challenging, particularly among women of child-bearing age. In 2015, notable steps were taken in the right direction, with work that provided insight into the diagnosis of epilepsy, management of this condition during pregnancy, and new treatment options. Full Text | PDF
Neurodegenerative disease in 2015: Targeting tauopathies for therapeutic translation Julio C. Rojas & Adam L. Boxer Published online: 22 January 2016 p74 | doi:10.1038/nrneurol.2016.5 Tau protein abnormalities are key pathogenic features of Alzheimer disease and other neurodegenerative diseases. In 2015, new studies of the less common tauopathies, including progressive supranuclear palsy, chronic traumatic encephalopathy and frontotemporal lobar degeneration, have identified in vivo biomarkers and mechanisms that initiate tau pathology. Full Text | PDF
REVIEWS		Top
Hepatitis E virus and neurological injury Harry R. Dalton et al. Published online: 29 December 2015 p77 | doi:10.1038/nrneurol.2015.234 Hepatitis E virus (HEV) is the causative agent of hepatitis E, and extrahepatic manifestations, including various types of neurological injury, have also been reported in individuals with HEV infection. The most common neurological manifestations are Guillain-Barre syndrome (GBS), neuralgic amyotrophy, and encephalitis and/or myelitis. In this article, the authors review the reported cases of HEV-associated neurological injury, discuss the possible pathogenic mechanisms, and outline future directions and research questions. Abstract | Full Text | PDF | Supplementary information
Randomized trials of endovascular therapy for stroke — impact on stroke care Maxim Mokin, Haydy Rojas & Elad I. Levy Published online: 18 January 2016 p86 | doi:10.1038/nrneurol.2015.240 2015 saw the publication of five randomized controlled trials of endovascular treatment for acute stroke caused by vascular occlusion, with huge implications for the future of patient management. Mokin and colleagues consider the findings of these trials in the context of their designs, in particular the criteria for patient selection, and their likely impact on future management of acute stroke. Abstract | Full Text | PDF
CCR5 blockade for neuroinflammatory diseases — beyond control of HIV Guillaume Martin-Blondel et al. Published online: 18 January 2016 p95 | doi:10.1038/nrneurol.2015.248 The chemokine receptor CCR5 is thought to have a role in several CNS inflammatory diseases and infections. The role of CCR5 in HIV has already led to the development of effective and well-tolerated CCR5 antagonists, which could offer a readily available option for the treatment of CNS diseases. In this Review, Martin-Blondel et al. consider the evidence for a role of CCR5 in several CNS diseases and the rationale for use of CCR5 anatagonists in these conditions. Abstract | Full Text | PDF
Management of psychiatric and neurological comorbidities in epilepsy Andres M. Kanner Published online: 18 January 2016 p106 | doi:10.1038/nrneurol.2015.243 Psychiatric and neurological comorbidities are relatively common in epilepsy, affecting 30-50% of patients. Neurologists should be able to treat psychiatric comorbidities in patients with epilepsy and identify patients at risk of adverse events from psychotropic medications, because psychiatric care is not available to all patients. In this Review, Andres Kanner discusses the complex relationship between epilepsy and psychiatric and neurological comorbidities, and provides considerations for selection of antiepileptic and psychotropic drugs in patients with epilepsy. Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Suspected non-Alzheimer disease pathophysiology — concept and controversy Clifford R. Jack, Jr et al. Published online: 18 January 2016 p117 | doi:10.1038/nrneurol.2015.251 Suspected non-Alzheimer disease pathophysiology (SNAP) is a biomarker-based concept that applies to individuals with normal levels of amyloid-β biomarkers in the brain, but in whom biomarkers of neurodegeneration are abnormal. Clinically normal and mildly impaired individuals with SNAP are at increased risk of poor clinical and cognitive outcomes. In this Perspectives article, Clifford Jack and colleagues describe the available data on SNAP and address topical controversies in the field. Abstract | Full Text | PDF | Supplementary information
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2015. Nature Reviews Neurology was previously published as Nature Clinical Practice Neurology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.